ovarian cancer

An International Analysis of Treatments and Outcomes Among Patients with Epithelial Ovarian Cancer

Results from a study presented at the virtual 2021 ASCO Annual Meeting suggest variation in patient populations between sites, and differences in treatments and outcomes across international networks of epithelial ovarian cancer treatment centers.

Geoff Hall, MD, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom presented these results.

Aiming to address the lack of major studies comparing the management and outcomes of patients from diagnosis to death between countries, Dr Hall and colleagues compared treatments and outcomes across Europe and South Korea among patients with epithelial ovarian cancer.

A total of 2925 patients who were diagnosed with epithelial ovarian cancer between January 2012 and December 2018, with a median age of 53 to 67 years, were analyzed for this study, using the data of medical records from 6 treatment centers (5 European, and 1 South Korean).  Kaplan Meier Methods were used to estimate the time to next treatment and overall survival, which were stratified by categories of interest.

Reports showed that in all of the treatment centers included in this study, advanced disease and high-grade serous morphology were most common. The timing of surgery and the proportion of patients undergoing surgery changed between stages. Surgery was the most common in patients in stage one, and least common in patients in stage IV.

The median overall survival for the whole cohort ranged from 2.1 to 5.5 years, and in patients with high grade serous cancers, 1.9 to 4.9 years. The median time to next treatment was between 14 and 22 months.

Overall, 6% to 17% of patients had a second breast cancer, occurring most frequently before the diagnoses of epithelial ovarian cancer at a median time of 96 to 118 months prior to diagnosis of epithelial ovarian cancer.

“Preliminary analysis of results across this network suggests a variation in patient populations between sites and substantial differences in both treatments and outcomes” wrote Dr Hall and colleagues, adding, “The establishment of a common data model and the use of a common analytic script between sites across six different countries allows for detailed exploration of the factors influencing differences in patient management and treatment outcomes in ovarian cancer patients.”

 

—Marta Rybczynski

 

Reference:

Hall G, Cheeseman S, Levick B, et al. An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes. Presented at: the 2021 ASCO Annual Meeting; June 4-8, 2021; virtual. Abstract 5531.